Orlando, FL -- (SBWIRE) -- 10/02/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On GTx, Inc. (NASDAQ:GTXI), ProShares Trust II (NYSEARCA:UVXY).
GTx, Inc. (NASDAQ:GTXI) stock declined 7.16% to $1.88. The company on Sept. 24 announced that top line results from the two Phase 3 trials on the effects of enobosarm for the prevention and treatment of muscle wasting in non-small cell lung cancer patients will be presented on September 28, 2013, at the European Cancer Congress 2013 (September 27-October 1, 2013) in Amsterdam.
Jeffrey Crawford, M.D., Chief, Division of Medical Oncology at Duke University School of Medicine, and principal investigator for the POWER1 and POWER2 clinical studies presented the results on September 28th, 2013 at 1:39PM (Elicium 2) during the Proffered Papers Session: Lung Cancer - Localised and Metastatic (11:00-14:00).
The abstract number is LBA 21: Results from two Phase 3 randomized trials of enobosarm, selective androgen receptor modulator (SARM), for the prevention and treatment of muscle wasting in NSCLC.
Are investors worried about the recent updates with GTXI? Find out with a free trend analysis HERE
ProShares Trust II (NYSEARCA:UVXY) shares dropped 6.79% and closed at $32.01 in the last trading session. The 52 week trading range for the company is $28.88 - $368.60. The shares of UVXY plunged 89% in the last one year.
Is UVXY going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)